New TSCA Inventory Released by EPA Lists Active Chemicals

February 25, 2019

The EPA has released what it describes as the first update of the Toxic Substances Control Act (TSCA) Inventory in 40 years. The update indicates that 47 percent of the 86,228 chemicals listed on the Inventory are “active,” which means they have been manufactured, processed, or imported for a nonexempt commercial purpose during the 10-year “lookback” period ending on June 21, 2016, the enactment date of the 2016 TSCA amendments.Determining if a chemical is on the Inventory is a critical step before beginning to manufacture, process, or import a chemical substance. For purposes of regulation under TSCA, if a chemical is on the Inventory, the substance is considered an existing chemical substance in U.S. commerce. Any chemical that is not on the Inventory is considered a “new chemical substance.” Section 5 of TSCA requires that anyone who plans to manufacture a new chemical substance for a nonexempt commercial purpose must provide the EPA with a Premanufacture Notice (PMN) at least 90 days before initiating the activity.

Spotlight

PharmaVentures

PharmaVentures is a leading advisory firm in specialising in deals and alliances. The company largely focuses on M&A and Licensing mandates. With over 24 years of experience, PharmaVentures is trusted as a sell-side or buy-side advisor by a wide range of life sciences companies that include both large blue-chip pharmaceutical companies as well as mid-sized pharmaceutical companies, biotech/medtech companies, other life science players and private equity firms. In March 2016, 3Legs Resources appointed PharmaVentures as an adviser on the acquisition of SalvaRx, a company working in immuno-oncology. In February 2016, PharmaVentures acted as adviser to Transgene on the sale of its biopharmaceutical manufacturing unit in Strasbourg, France, to the US company Advanced Bioscience Laboratories (ABL), Inc.

OTHER ARTICLES

Transporting biological and chemical materials - what you need to know

Article | February 13, 2020

The landscape of biological and chemical logistics has changed rapidly - as have the regulatory frameworks around it. What has not necessarily kept pace is the end-user understanding of the nature of these logistical processes, their opportunities and their constraints. Twenty years ago, the transmission of biological and chemical materials was limited to a small range of organisations: usually national and international research companies, hospitals, major university departments, police and military departments with forensic responsibilities.

Read More

Setting record straight on testing harm in chemicals

Article | February 13, 2020

The modern world is built on chemicals, be it the medicines we use, or cleaning fluids, crop protection products, or the raw materials for everything from laptops and mobile phones to clothes and furniture. Across all, we have created an entire modern society with chemicals, and, as a result, constantly stretched the size of the world population we can feed, clothe and shelter. Yet, balancing all the gains from the modern chemistry around us against any negative environmental and human impact has been a rising concern, making for ever greater focus on testing and on risk assessment.

Read More

Why chemical characterization is the best way to assess patient risk

Article | February 11, 2020

Everyone is very familiar with the phrase when buying a house: All that really matters are three things - location, location, and location. This same principle applies to extractables and leachables chemistry analysis – the three things that truly matter are identification, identification, and identification. The greatest growth in the past ten years in demonstrating the safety of medical devices and container closure systems for drugs has been using analytical chemistry to determine what chemicals can leach from the device and what the patient is exposed to during its intended use.

Read More

How Chemical Companies Benefit from the Experience Economy

Article | February 10, 2020

To feel or experience from a business engagement started with customer experience mainly in the consumer products business. Today it has extended to even knowledge industries like the chemical industry where experiencing or feeling can be leveraged to include all stake holders from customers primarily to employees to supply chain people & suppliers and all else. With digital technologies this has become easier than before. The benefits from promoting the ‘feel’ or ‘experience’ emotion could be multifarious for the chemical industry as described in this article.

Read More

Spotlight

PharmaVentures

PharmaVentures is a leading advisory firm in specialising in deals and alliances. The company largely focuses on M&A and Licensing mandates. With over 24 years of experience, PharmaVentures is trusted as a sell-side or buy-side advisor by a wide range of life sciences companies that include both large blue-chip pharmaceutical companies as well as mid-sized pharmaceutical companies, biotech/medtech companies, other life science players and private equity firms. In March 2016, 3Legs Resources appointed PharmaVentures as an adviser on the acquisition of SalvaRx, a company working in immuno-oncology. In February 2016, PharmaVentures acted as adviser to Transgene on the sale of its biopharmaceutical manufacturing unit in Strasbourg, France, to the US company Advanced Bioscience Laboratories (ABL), Inc.

Events